Latest News
Generate Biomedicines, Inc.
- Zealand taps Generate’s AI for obesity proteins in nearly $1.2b deal
- Generate Biomedicines to Participate in November Investor Conferences
- Generate Biomedicines to Participate in November Investor Conferences
- Why Is Generate Biomedicines (NASDAQ:GENB) Up 4.65% Premarket?
- Why Did Generate Biomedicines (NASDAQ:GENB) Gain 4.44% to USD 12.80?
- Zealand Pharma and Generate Biomedicines team up on AI-designed obesity therapies
- Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion
- Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline
- Generate Biomedicines, Zealand Pharma Report Partnership
- Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
- Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm (NASDAQ:GENB)
- Generate Biomedicines and Roswell Park dose first patient in AI-designed CAR T therapy trial for ovarian cancer
Headlines from the last 30 days, linking to the original publishers. See all market news →